latest update:
[TrialBase DB]

trial summary · NCT07862647

TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma

A Phase 1 Clinical Trial Evaluating the Safety and Tolerability of Bilateral Hemispheric 5-ALA-Mediated Sonodynamic Therapy Using the LIDU System Before Standard Radiochemotherapy and During Adjuvant Temozolomide in Patients With Histologically Proven Newly Diagnosed Butterfly Glioma

Trial record from the TrialBase DB dataset, status RECRUITING, condition Glioblastom WHO Grade 4, sponsored by Alpheus Medical, Inc.. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07862647phase PHASE1enrollment 30start 2026-10-29

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This study is assessing the safety and tolerability of 5-ALA- mediated Porphyrin Metabolite Activation (PoMA) with LIDU ultrasound, in patients who have just been diagnosed with bihemispheric (in both sides of the brain) glioblastoma, sometimes called butterfly glioblastoma, before they complete their standard of care chemotherapy and radiation and after their standard of care chemotherapy and radiation while they are receviing their standard of care adjuvant chemotherapy.

Source record: https://clinicaltrials.gov/study/NCT07862647

Facts

registry idNCT07862647
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1
study typeINTERVENTIONAL
lead conditionGlioblastom WHO Grade 4
sponsorAlpheus Medical, Inc.
sponsor classINDUSTRY
enrollment30
start date2026-10-29
primary completion2027-10-30
completion2028-03-30
results postednot reported

Conditions

  • Glioblastom WHO Grade 4
  • GBM
  • bGBM
  • Butterfly GBM
  • Bihemispheric GBM
  • Glioblastoma

Interventions

  • 5-ALA
  • Porphyrin Metabolite Activation (PoMA) with LIDU ultrasound

Countries

  • United States

Intervention types: DEVICE, DRUG

Work with this record